New Reagent Red Cell Products Unveiled at Annual Blood Banking Meeting
By LabMedica International staff writers Posted on 03 Nov 2014 |
Image: Quotient manufactures a range of reagent red cells for use in both patient and donor testing applications. All panels are manufactured from pre-selected donors, thus providing consistent high quality products (Photo courtesy of Quotient Limited).
Four new reagent red cell diagnostic products were unveiled at a blood banking meeting.
The annual meeting of the American Association of Blood Banks (AABB) that was held in Philadelphia, PA, USA from October 25–28, 2014, was selected for the launch of new red cell reagent diagnostic products produced by Quotient Limited (St Helier, Jersey).
The four new products are: (1) ALBAcyte Expanded Rh Negative Antibody Screen, (2) ALBAcyte Antibody Identification Panel (16-cell), (3) ALBAcyte Antibody Screen (two-cell), and (4) ALBAzyme Papain Solution Kit.
The ALBAcyte Expanded Rh Negative Antibody Screen will be of particular use with pregnant, Rh-negative women who have been treated with Rh immunoglobulin. Its Rh-negative cells detect all the unexpected antibodies required of traditional screens. The ALBAcyte Antibody Identification Panel (16-cell) is a full antibody identification panel with six complementary cells. The ALBAcyte Antibody Screen (two-cell) is a robust antibody screen for those laboratories that prefer a two-cell screen, or frequently test pediatric or other small-volume samples. Red cells incorporated in this product have been carefully selected to maximize homozygosity, thus optimizing the detection of antibodies. The ALBAzyme Papain Solution Kit is a kit combining both papain and enzyme control, which pairs with the existing papain-treated ALBAcyte Antibody Identification Panel (10-cell), to better allow laboratories to treat and test auto-controls and patient samples.
"These four new products expand our reagent red cell offering, including the addition of a number of novel products," said Jeremy Stackawitz, president of Quotient Limited. "Quotient's product offering can now address all the needs of the vast majority of blood bank laboratories, truly making it a one-stop-shop for reagent red cells."
Related Links:
Quotient Limited
The annual meeting of the American Association of Blood Banks (AABB) that was held in Philadelphia, PA, USA from October 25–28, 2014, was selected for the launch of new red cell reagent diagnostic products produced by Quotient Limited (St Helier, Jersey).
The four new products are: (1) ALBAcyte Expanded Rh Negative Antibody Screen, (2) ALBAcyte Antibody Identification Panel (16-cell), (3) ALBAcyte Antibody Screen (two-cell), and (4) ALBAzyme Papain Solution Kit.
The ALBAcyte Expanded Rh Negative Antibody Screen will be of particular use with pregnant, Rh-negative women who have been treated with Rh immunoglobulin. Its Rh-negative cells detect all the unexpected antibodies required of traditional screens. The ALBAcyte Antibody Identification Panel (16-cell) is a full antibody identification panel with six complementary cells. The ALBAcyte Antibody Screen (two-cell) is a robust antibody screen for those laboratories that prefer a two-cell screen, or frequently test pediatric or other small-volume samples. Red cells incorporated in this product have been carefully selected to maximize homozygosity, thus optimizing the detection of antibodies. The ALBAzyme Papain Solution Kit is a kit combining both papain and enzyme control, which pairs with the existing papain-treated ALBAcyte Antibody Identification Panel (10-cell), to better allow laboratories to treat and test auto-controls and patient samples.
"These four new products expand our reagent red cell offering, including the addition of a number of novel products," said Jeremy Stackawitz, president of Quotient Limited. "Quotient's product offering can now address all the needs of the vast majority of blood bank laboratories, truly making it a one-stop-shop for reagent red cells."
Related Links:
Quotient Limited
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data